Pharm Ingredients
Hyodeoxycholic Acid Powder
Hyodeoxycholic Acid Powder Manufacturers
Kintainutri® Hyodeoxycholic Acid (HDCA) powder is a secondary bile acid extracted from the bile of healthy pigs. Chemically known as 3α,6α-dihydroxy-5β-cholanic acid, it has the molecular formula C₂₄H₄₀O₄. The product appears as a white powder that is sparingly soluble in water but readily soluble in ethanol. In the pharmaceutical field, HDCA regulates lipid metabolism and lowers blood cholesterol and triglyceride levels, making it suitable for managing hyperlipidemia and atherosclerosis; it also alleviates hepatic lipid accumulation and inflammation, showing potential therapeutic value for non-alcoholic fatty liver disease.
Additionally, HDCA offers choleretic, digestive-enhancing, anti-inflammatory, and antibacterial properties, serving as an adjuvant therapy for conditions such as biliary tract disorders and chronic bronchitis. Produced from high-quality raw materials, Kintainutri® HDCA features high purity (98%) and excellent batch-to-batch consistency, meeting the application requirements of sectors ranging from pharmaceutical R&D to functional foods and feed additives.
Hyodeoxycholic Acid Powder Specification
| Test Item | Specification | Test Method |
|---|---|---|
| Appearance | White powder | Visual |
| Odor & Taste | Odorless or slight characteristic odor, bitter taste | Organoleptic |
| Assay (Purity) | ≥ 98.0% (Dry basis) | HPLC |
| Melting Point | 195.0°C - 200.0°C | Melting Point Apparatus |
| Specific Rotation | +7.0° to +10.0° | Polarimetry |
| Loss on Drying | ≤ 1.0% | GB 5009.3 / USP <731> |
| Residue on Ignition (Ash) | ≤ 0.2% | USP <281> |
| Related Substances – Individual Impurity | ≤ 0.5% | HPLC |
| Related Substances – Total Impurities | ≤ 1.5% | HPLC |
| Total Heavy Metals | ≤ 10.0 ppm | Colorimetry |
| Lead (Pb) | ≤ 1.5 mg/kg | ICP-MS |
| Arsenic (As) | ≤ 0.5 mg/kg | ICP-MS |
| Cadmium (Cd) | ≤ 0.5 mg/kg | ICP-MS |
| Mercury (Hg) | ≤ 0.1 mg/kg | ICP-MS |
| Total Plate Count | ≤ 1,000 CFU/g | GB 4789.2 |
| Yeast & Mold | ≤ 100 CFU/g | GB 4789.15 |
| E. Coli | Negative / 10g | GB 4789.38 |
| Salmonella | Negative / 25g | GB 4789.4 |
| Staphylococcus aureus | Negative / 25g | GB 4789.10 |
How To Make Hyodeoxycholic Acid Powder?
Hyodeoxycholic Acid Powder Benefits
HDCA for Liver Health
HDCA (hyodeoxycholic acid) promotes the nuclear accumulation of PPARα by directly binding to the RAN protein and blocking the formation of the RAN/CRM1/PPARα nuclear export trimer. This process activates the expression of genes associated with fatty acid oxidation, thereby significantly enhancing hepatic fat burning, reducing lipid accumulation, and inhibiting inflammatory responses. Studies in animal models have demonstrated that HDCA significantly improves hepatic steatosis, inflammation scores, and liver function markers (ALT/AST) associated with non-alcoholic fatty liver disease (NAFLD), while exhibiting a favorable safety profile.
As an active ingredient with novel targets and strong academic backing, HDCA powder offers differentiated commercial value for pharmaceutical research and development as well as functional food applications.
Hyodeoxycholic Acid For Atherosclerosis
Hyodeoxycholic acid antagonizes the FXR receptor and inhibits PD-1 expression on the surface of Treg cells, thereby relieving the inhibition of the mTORC1 pathway. This drives a metabolic reprogramming of Treg cells from oxidative phosphorylation to glycolysis, providing sufficient energy for cytoskeletal rearrangement and migration, and promoting the accumulation of Treg cells within atherosclerotic plaques. Within the plaques, Treg cells exert immunosuppressive functions by secreting the anti-inflammatory cytokines IL-10 and IL-35; this reduces local inflammation, increases collagen deposition, stabilizes plaque structure, and ultimately significantly alleviates atherosclerotic lesions.
These findings demonstrate that HDCA Bile Acid is not only a therapeutic candidate for NAFLD but also holds significant potential for application in the field of cardiovascular disease. Given the large global patient population, HDCA, as a multifunctional active ingredient targeting both metabolic and cardiovascular diseases, offers significant commercial potential.
Hyodeoxycholic Acid HDCA For Sepsis
As an endogenous TLR4 antagonist, HDCA directly binds to the TLR4/MD2 complex, competitively blocking the interaction between LPS and TLR4 and inhibiting the overactivation of downstream MAPK and NF-κB inflammatory signaling pathways; consequently, it significantly alleviates systemic inflammation and multi-organ injury while prolonging survival in septic mice.
HDCA levels are markedly reduced in both septic patients and mice and show an inverse correlation with disease severity, a decrease associated with reduced abundance of HDCA-producing gut microbiota. With a favorable safety profile and a clearly defined target, hyodeoxycholic acid powder holds broad application prospects; beyond sepsis, excessive TLR4 activation is implicated in conditions such as atherosclerosis, neuropathic pain, and autoimmune diseases.
What Is Hyodeoxycholic Acid Powder Used For?
HDCA in Pharmaceuticals
Hyodeoxycholic acid powder holds broad prospects for application in the pharmaceutical field. Regarding hepatic metabolic diseases, it can significantly ameliorate non-alcoholic fatty liver disease by reducing hepatic fat accumulation and inflammation, as well as improving markers of liver function. In the cardiovascular realm, hyodeoxycholic acid can alleviate the burden of atherosclerotic plaques and stabilize plaque structure.
In terms of anti-inflammatory effects, it inhibits the excessive inflammatory response associated with sepsis and reduces multi-organ damage. Furthermore, it shows promise for exploration in the treatment of metabolic disorders such as primary biliary cholangitis, diabetes, and obesity. As an endogenous bioactive substance with a favorable safety profile, hyodeoxycholic acid is a highly promising, multifunctional pharmaceutical raw material.
Feed Additive
Hyodeoxycholic acid (HDCA) shows promising potential for application as a feed additive. Supplementing the diets of weaned piglets with 2 g/kg of HDCA modulates the differentiation of intestinal endocrine cells; it significantly elevates serum globulin, IgA, and IgG levels and enhances humoral immune function without compromising growth performance or intestinal morphology.
By regulating transcription factor networks, HDCA exerts region-specific effects on the differentiation trajectory of intestinal endocrine cells, promoting the differentiation of D cells and G cells in the jejunum. As an endogenous bile acid, HDCA Bile Acid possesses a favorable safety profile and holds significant value for development in the fields of animal nutrition and immunology.
Hyodeoxycholic Acid Powder Safety &Side Effects
HDCA has shown good tolerance in animal experiments, and no obvious adverse reactions or organ toxicity were observed, but its potential side effects still require attention. Theoretically, as a bile acid substance, HDCA may cause gastrointestinal discomfort, such as diarrhea, abdominal pain or nausea; although liver function abnormalities are rare and usually dose-related, people with previous severe liver disease or cirrhosis should use it with caution, as changes in bile acid composition may aggravate the condition.
In addition, those with a history of gastrointestinal diseases are advised to consult a professional physician before use, and those allergic to bile acids should avoid use. Taken together, the safety foundation of hyodeoxycholic acid powder is good, but clinical application still needs more support from systemic toxicology and clinical trial data.
Kintainutri® Hyodeoxycholic Acid Powder Advantages
Kintainutri® Hyodeoxycholic Acid (HDCA) powder is a secondary bile acid extracted from healthy porcine bile, appearing as a white powder. As an endogenous bioactive substance, HDCA not only facilitates fat emulsification and absorption but also serves as a multifunctional signaling molecule, playing a vital role in regulating metabolism, inflammatory responses, and immune function.
Kintainutri® HDCA is produced using premium raw materials and standardized manufacturing processes, ensuring 98% purity and excellent batch-to-batch consistency. We provide comprehensive technical support and customized services to assist clients throughout the entire process, from R&D to production. With high purity and full traceability, our product empowers your R&D and innovation efforts. Please feel free to contact us for more information or to request samples.
*Kintainutri® Promise All Products: Non-Irradiated / Non-ETO/ Treat by Heat Only / Non-GMO
Reference:
[1]: https://www.nature.com/articles/s41467-023-41061-8
[2]: https://www.sciencedirect.com/science/article/pii/S2213231726000947
[3]: https://www.sciencedirect.com/science/article/pii/S1525001623000187
[4]: https://pmc.ncbi.nlm.nih.gov/articles/PMC6447273/
[5]: https://en.wikipedia.org/wiki/Hyodeoxycholic_acid
[1]: https://www.nature.com/articles/s41467-023-41061-8
[2]: https://www.sciencedirect.com/science/article/pii/S2213231726000947
[3]: https://www.sciencedirect.com/science/article/pii/S1525001623000187
[4]: https://pmc.ncbi.nlm.nih.gov/articles/PMC6447273/
[5]: https://en.wikipedia.org/wiki/Hyodeoxycholic_acid
FAQ
-
What is hyodeoxycholic acid powder?
-
What is hyodeoxycholic acid powder medication used for?
About Us
